Multiple endocrine neoplasia

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Medical Supplies, Health, Medical Devices, Research, Science, Biotechnology, Methylation, Cervical cancer, Woman, ASCL1, Dysplasia, Triage, Partnership, Multiple endocrine neoplasia, Test management, Human papillomavirus infection, Fujirebio, Risk, SCC, Biomarker, RUO, Incidence, Patient, Carcinoma, Carcinogenesis, Gene, HPV, HSIL, Host, Anal cancer, Lithium, DNA methylation, DNA, IVD, Cancer, CIN, Vaccine

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

The National Osteoporosis Foundation (NOF) Announces Dr. Robert Gagel as the 2019 Recipient of its Lawrence G. Raisz Memorial Lecture Award

Retrieved on: 
Thursday, May 16, 2019
Glands, Organ systems, Endocrine system, Autosomal dominant disorders, Thyroid, Hereditary cancers, Multiple endocrine neoplasia type 2, Medullary thyroid cancer, Calcitonin, Multiple endocrine neoplasia

ARLINGTON, Va., May 16, 2019 /PRNewswire/ -- The National Osteoporosis Foundation (NOF) announces Robert Gagel, MD, Professor of Medicine at MD Anderson Cancer Center, Adjunct Professor in the Department of Cell Biology at Baylor College of Medicine and NOF Trustee, as the recipient of its 2019 Lawrence G. Raisz, MD Memorial Lecture Award.

Key Points: 
  • ARLINGTON, Va., May 16, 2019 /PRNewswire/ -- The National Osteoporosis Foundation (NOF) announces Robert Gagel, MD, Professor of Medicine at MD Anderson Cancer Center, Adjunct Professor in the Department of Cell Biology at Baylor College of Medicine and NOF Trustee, as the recipient of its 2019 Lawrence G. Raisz, MD Memorial Lecture Award.
  • "We are thrilled to announce Dr. Gagel as the recipient of NOF's highest scientific award, the Lawrence G. Raisz, MD Memorial Lecture Award," said Elizabeth Thompson, CEO, NOF.
  • Dr. Gagel is a renowned medical expert in Multiple Endocrine Neoplasia Type 2 (MEN2) and medullary thyroid carcinoma, as well as bone biology and calcitonin.
  • For more information on the National Osteoporosis Foundation, visit www.nof.org .